This study is looking at a drug called enfortumab vedotin for women with endometrial (uterine) cancer that has come back or gotten worse after previous treatments, including immunotherapy. Enfortumab vedotin works by targeting a protein on cancer cells. The study aims to see how well enfortumab vedotin works to shrink tumors and how safe it is. Up to 12 women aged 18 or older with specific types of recurrent endometrial cancer who have had prior surgery and other treatments may be able to join. Researchers will measure how many patients respond to the treatment and track any side effects for 24 months.

Study design

This is an open-label, single-arm Phase II study, meaning all 12 participants will receive enfortumab vedotin, and both you and your doctors will know what treatment you are getting.

What's involved

You would receive treatment for up to 12 months, or until your disease progresses, side effects are too severe, or you choose to stop. You would be monitored over time to track your health and response.

Compensation

Not stated in the trial record.

Follow-up

If you stop treatment for reasons other than disease progression, you will be followed for disease status until progression. Your overall response and safety will be evaluated for 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.